Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon

Berger, 2010, The molecular basis of human retinal and vitreoretinal diseases, Prog. Retin. Eye Res., 29, 335, 10.1016/j.preteyeres.2010.03.004 Cheng, 2010, Intravitreal crystalline drug delivery for intraocular proliferation diseases, Invest. Ophthalmol. Vis. Sci., 51, 474, 10.1167/iovs.09-3672 Peyman, 1985, Proliferative vitreoretinopathy and chemotherapeutic agents, Surv. Ophthalmol., 29, 434, 10.1016/0039-6257(85)90208-5 Shinohara, 2003, Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy, Ophthalmic Surg. Lasers Imaging, 34, 299, 10.3928/1542-8877-20030701-05 Khawly, 1991, Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy, Graefes Arch. Clin. Exp. Ophthalmol., 229, 464, 10.1007/BF00166311 Wiedemann, 1998, Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group, Am J. Ophthalmol., 126, 550, 10.1016/S0002-9394(98)00115-9 Kumar, 2002, Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery, Clin. Exp. Ophthalmol., 30, 348, 10.1046/j.1442-9071.2002.00554.x Wiedemann, 1985, Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo, Invest. Ophthalmol. Vis. Sci., 26, 719 Cheng, 2008, Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle, Br. J. Ophthalmol., 92, 705, 10.1136/bjo.2007.133587 Chhablani, 2013, Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system, Invest. Ophthalmol. Vis. Sci., 54, 1268, 10.1167/iovs.12-11172 Hartmann, 2013, Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin, J. Ocul. Pharmacol. Ther., 29, 493, 10.1089/jop.2012.0205 Nieto, 2013, Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles, Exp. Eye Res., 116, 161, 10.1016/j.exer.2013.09.001 Anderson, 2003, Dissolution of different forms of partially porous silicon wafers under simulated physiological conditions, Phys. Status Solidi A, 197, 331, 10.1002/pssa.200306519 Martinez, 2013, Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics, Biomaterials, 34, 8469, 10.1016/j.biomaterials.2013.07.049 Sailor, 2012 Wu, 2011, Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics, Chem. Commun. (Camb.), 47, 5699, 10.1039/c1cc10993f Wu, 2008, Oxidation-triggered release of fluorescent molecules or drugs from mesoporous Si microparticles, ACS Nano, 2, 2401, 10.1021/nn800592q Pacholski, 2005, Biosensing using porous silicon double-layer interferometers: reflective interferometric Fourier transform spectroscopy, J. Am. Chem. Soc., 127, 11636, 10.1021/ja0511671 K.S.W., 1982 Brunauer S., 1938, Adsorption of gases in multimolecular layers, J. Am. Chem. Soc., 60, 309, 10.1021/ja01269a023 Kruk, 1999, Relations between pore structure parameters and their implications for characterization of MCM-41 using gas adsorption and X-ray diffraction, Chem. Mater., 11, 492, 10.1021/cm981006e Kim, 2012, A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3′,5′-cyclic monophosphate for proliferative vitreoretinopathy, Mol. Vis., 18, 1907 Cheng, 1999, Intravitreal pharmacokinetics in rabbits of the foscarnet lipid prodrug: 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA), Curr. Eye Res., 18, 161, 10.1076/ceyr.18.3.161.5366 Bartz-Schmidt, 2008, New developments in retinal detachment surgery, Ophthalmologe, 105, 27, 10.1007/s00347-007-1662-2 Scheer, 2004, Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy, J. Fr. Ophtalmol., 27, 1051, 10.1016/S0181-5512(04)96264-X Wiedemann, 1983, Control of experimental massive periretinal proliferation by daunomycin: dose–response relation, Graefes Arch. Clin. Exp. Ophthalmol., 220, 233, 10.1007/BF02308080 Santana, 1984, Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit, Graefes Arch. Clin. Exp. Ophthalmol., 221, 210, 10.1007/BF02134142 Hou, 2011, Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation, Mol. Vis., 17, 627 Rahimy, 1994, Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations, J. Ocul. Pharmacol., 10, 561, 10.1089/jop.1994.10.561 Anglin, 2008, Porous silicon in drug delivery devices and materials, Adv. Drug Deliv. Rev., 60, 1266, 10.1016/j.addr.2008.03.017 Regillo, 2008, Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1, Am J. Ophthalmol., 145, 239, 10.1016/j.ajo.2007.10.004 Davson, 1959, Chemistry and rate of turnover of the ocular fluids of the bush baby (Galago crassicaudatus Agisymbanus), J. Physiol., 145, 433, 10.1113/jphysiol.1959.sp006151 Zhang, 2006, Porous silicon: morphology and formation mechanisms, Mod. Asp. Electrochem., 39, 65, 10.1007/978-0-387-31701-4_2